DHL Life Sciences and Health Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was the integration process to you as a former Exel director? Exel Brazil first got involved in the life science business…
Department of Health And Ageing New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs of the 21st century, including the growing burden of chronic disease. Bringing a greater focus to prevention in health policy…
IMS Health Australia How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS since your arrival in December 2007? Having been a client gives insights into the client side, and perspective on what…
IMS Health Argentina It’s safe to assume that everywhere that IMS Health is established, there’s also a flourishing pharmaceutical industry. Could you give us an overview of Argentina’s IMS operations? IMS has been in Argentina for 35 years, working in information services. Two years ago, we started to offer our customers consulting services.…
IMS Health South Africa Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio? For us, like many other multinationals (MNCs), South Africa remains a vibrant growth market. It is a country that we…
IMS Health South Africa Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not a commodity generics market. The brand is important in South Africa and a lot of our generics are not International…
IMS Health Hungary IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from the other markets in the region? I believe none of the countries of the region is having a good time…
National Health Insurance House of Romania (CNAS) If we first take a look at the healthcare system in Romania, it is clear that finding adequate funding has been a key challenge for many years. With 3.6% of GDP being spent on healthcare, Romania equals levels of countries such as Burundi and Bangladesh. In your view, what were…
Bayer Healthcare Pharmaceuticals Russia You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed, and what do you find most striking? The biggest difference is the fact that the government is much more involved…
Ministry of Health Voivodeships, Polish expenditure on health care system per one resident is still below the European average. In regards to the issue concerning the „expenditure on health care system”, I would like to inform you that the financial plan of the National Health Fund for 2011 provides that costs of health…
IMS Health Netherlands IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market? There are quite a few particularities. When we discuss the value of the pharmaceutical market in the Netherlands for example,…
Atlantic Healthcare Ltd A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status was granted in Europe. Many companies in the UK have named market access as a key challenge—but is that an…
See our Cookie Privacy Policy Here